Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
February 19, 2026Clinical Cancer Research

Abstract PS4-03-29: N-nose as a non-invasive biomarker for predicting neoadjuvant chemotherapy response in breast cancer patients

View Full Paper
Ask AI
Bookmark
Share

Authors

ANAkira NakakamiYTYoshihisa TokumaruYNY. Niwa

Discussion

Loading...

Member takes

Overview

This prospective study demonstrates the N-NOSE method's ability to predict chemotherapy outcomes in breast cancer, highlighting its potential as a reliable diagnostic tool.

Key Points

  • To evaluate the predictive ability of the N-NOSE method for neoadjuvant chemotherapy response in breast cancer patients.
  • Enrolled 36 breast cancer patients for neoadjuvant chemotherapy and surgery.
  • Collected urine samples at three time points: before chemotherapy, before surgery, and four weeks post-surgery.
  • Conducted chemotactic assays using C. elegans and calculated the chemotaxis index and Index Reduction Score.
  • 13 patients (36.1%) achieved pathological complete response (pCR), and 16 patients (44.4%) achieved partial response (pPR).
  • AUC for the response indicator showed variations: 0.53 for IRS1, 0.76 for IRS2, and 0.66 for IRS3, indicating IRS2 had the highest predictive ability.
  • Analysis specific to pCR revealed AUCs of 0.58 for IRS1, 0.64 for IRS2, and 0.75 for IRS3.

Cite This Study

Nakakami et al. (2026) studied this question.

synapsesocial.com/papers/6996a84cecb39a600b3eed26https://doi.org/10.1158/1557-3265.sabcs25-ps4-03-29
View Full Paper
Ask AI
Bookmark
Share